Anti-Human CFD Reference Antibody (Lampalizumab, RUO) (HF697016)

Name: Anti-Human CFD Reference Antibody (Lampalizumab, RUO)
Brand: abinScience
SKU: HF697016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HF697016
Description	Lampalizumab (HF697016) is a research-grade recombinant antibody targeting PFD. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	Fab-G1-kappa
Système d'expression	Mammalian cells
Cible	PFD, Adipsin, C3 convertase activator, Complement factor D, CFD, DF, Properdin factor D
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P00746
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	AFD, Anti-fD, Anti-FACTORD, FCFD4514S, RG7417, 1278466-20-8
Contexte	Complement factor D (CFD) is a ~27 kDa protein. Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3. The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases. Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway. 1. Forneris, F. et al. (2010) Science (New York, N.Y.) 330, 1816-20. PMID: 21205667 2. Katschke, KJ. et al. (2012) The Journal of biological chemistry 287, 12886-92. PMID: 22362762 3. Niemann, MA. et al. (1980) Biochemistry 19, 1576-83. PMID: 6769474 4. Volanakis, JE. et al. (1977) Journal of immunology (Baltimore, Md. : 1950) 119, 337-42. PMID: 874324 5. Hourcade, DE. et al. (1998) The Journal of biological chemistry 273, 25996-6000. PMID: 9748277
Note	For research use only. Not suitable for clinical or therapeutic use.